Navigation Links
Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
Date:3/9/2009

SAN DIEGO, March 9 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce its fourth quarter and year ended December 31, 2008 financial results on Thursday, March 12, 2009 after the markets close. The announcement will be followed by a live webcast and conference call at 2:00 p.m. Pacific time.

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (800) 860-2442 (domestic) or (412) 858-4600 (international). The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase III clinical trials, and Empatic(TM) which is in the later stages of Phase II development. Both product candidates take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
2. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
3. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
4. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
5. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
6. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
7. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
8. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
9. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
10. Nile Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results and Announces Conference Call on March 10, 2009
11. ExonHit Therapeutics Shareholders Equity Strengthened by Exercise of More Than Half of its Convertible Bonds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015   Tocagen Inc. , a clinical-stage ... Parkinson , M.D., a venture partner at New ... board of directors of Tocagen. Dr. Parkinson has ... clinical development, including leading clinical activities at Amgen ... the cancer therapeutics Gleevec®, Femara®, Zometa®, Kepivance® and ...
(Date:5/5/2015)... 5, 2015  Indianapolis-based medical device manufacturer NICO ... line of products including the BrainPath® and Myriad™ ... deep-seated brain abnormalities and then removing affected tissue. ... more than 50 institutions throughout the ... been included in 12 abstracts, three peer-reviewed publications, ...
(Date:5/4/2015)... 2015 Many of us take a ... infants with rare, inherited mutations of certain genes, ... their impaired immune responses. Now, researchers ... important role for calcium signaling in immune responses ... bacterium causing tuberculosis (TB). Specifically, ...
(Date:5/4/2015)... MEMPHIS, Tenn. , May 4, 2015 /PRNewswire-USNewswire/ ... have developed a significantly better computer tool for ... in many cancers but were difficult to identify ... the scientific journal Nature Methods . ... short for Copy Number Segmentation by Regression Tree ...
Breaking Biology Technology:Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 2NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 3Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3Scientists dramatically improve method for finding common genetic alterations in tumors 2Scientists dramatically improve method for finding common genetic alterations in tumors 3Scientists dramatically improve method for finding common genetic alterations in tumors 4
... growth rose slightly, with 17,000 more jobs created in April. Though there ... overall is off by about 40 percent compared to 2008. , ... ... in healthcare off by about 40 percent from first quarter 2008, job ...
... Germany, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) ... has just been approved by the responsible Grants ... Research Training Groups offer doctoral researchers the opportunity ... and qualification programme at a high level of ...
... ) last week analyzed the most recent peptide ... infectivity of the H1N1 virus will increase markedly, ... the immediate future. The company,s quantitative analysis of ... a standard scientific repository for published papers, showed ...
Cached Biology Technology:The MedZilla Report: April 2009 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: April 2009 Employment Outlook for Biotech/Pharma/Health 3DFG establishes 14 new research training groups 2DFG establishes 14 new research training groups 3DFG establishes 14 new research training groups 4DFG establishes 14 new research training groups 5DFG establishes 14 new research training groups 6DFG establishes 14 new research training groups 7Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data 2Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data 3
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... 23, 2015, after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... are hard to beat. They can adhere to virtually ... in saltwater, including turbulent tidal environments. Little is known, ... feat. , In a paper to be published online ... the National Academy of Sciences, a Northwestern University research ...
... two more cardiac genes to the list of potential ... possibility that genetic defects of the heart may cause ... will be presented Friday at Heart Rhythm 2006, the ... in Boston. , In the two recent separate studies, ...
... up while hibernating may be an evolutionary mechanism to fight ... could offer an insight into the spread and emergence of ... health. , Many warm-blooded animals slip into an ... get past harsh winters when food supplies are low and ...
Cached Biology News:Study reveals details of mussels' tenacious bonds 2Researchers link two more genes to sudden infant death syndrome 2Breaks in hibernation help fight bugs 2
... analysis of gene expression) technology ... Expression profiles generated by SAGE ... low-abundance transcripts making it possible ... I-SAGE Kit is designed to ...
Incomplete Adjuvant...
2,4-Dinitrophenyl hapten is conjugated to Keyhole Limpet (KLH) protein through lysine....
...
Biology Products: